LTRN News & Events

Lantern Pharma has scheduled a Type C meeting with the U.S. Food and Drug Administration for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who have progressed following any TKI-based treatment- a population carrying a particularly poor prognosis and limited remaining therapeutic options. Lantern is seeking the FDA's scientific guidance to sharpen the trial design around the patients most likely to benefit, and to pursue the most rigorous and efficient development path possible.Preliminary clinical data from the HARMONIC trial, with a data cutoff of April 13, 2026, have revealed a differentiated and consistent progression-free survival profile for LP-300 in patients harboring the EGFR Exon 21 L858R mutation - accounting for approximately 40% of all EGFR-mutant NSCLC cases globally, and a subgroup with a notably inferior prognosis following frontline TKI therapy compared with Exon 19 deletion patients. Among L858R patients in HARMONIC, those who completed 6 doses or cycles of LP-300 demonstrated a higher median PFS than the overall L858R cohort and those patients that had only 4 doses or cycles of LP-300. These outcomes were observed in patients who had already progressed on tyrosine kinase inhibitor therapy - a setting where prognosis is particularly challenging and where treatment tolerability is a critical consideration. The upper confidence interval for mPFS for the L858R patient group remains not calculable at the time of analysis, suggesting that a meaningful proportion of patients may be achieving disease control that extends substantially beyond the reported median. The Hazard Ratio observations to date for the L858R patient group are also encouraging.

Lantern Pharma announced that withZeta.ai, a comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development, is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai, spanning introductory, academic, and commercial tiers, and represent a new, non-dilutive revenue stream for Lantern Pharma shareholders. The platform's commercial debut will be showcased through two landmark events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026, and public demonstrations at the American Association for Cancer Research Annual Meeting 2026 in San Diego at Booth 5054 during April 17-22.

Investor sentiment continues to hinge on developments out of the Middle East, and the market is still not buying the latest salvo from President Trump that U.S. negotiators are in "serious discussions" to end the war.  After opening broadly higher, indices ended the day mixed, with S&P 500's decline of 0.4% bringing the benchmark index within a percentage point of an official correction territory.  While the Vix retreated modestly, it remains above the 30 handle, and while Treasury yields saw a sharp reversal from the steel ascend since the start of the Iran campaign, the 10-year is still over 30bps higher as traders remains concerned by the inflationary slowdown as a result of rising energy prices.   Cyclical Industrials and Technology sectors were the worst performers, while defensively-oriented Staples and Utilities outperformed.  In the evening hours, futures are little changed, though commodities are showing continued strain, with WTI Crude Oil futures up for fourth straight session, topping $104 per barrel.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Spruce Powerup 6.0%Progress Softwareup 1.3%DOWN AFTER EARNINGS -Phreesiadown 22.0%CVD Equipmentdown 10.8%Lantern Pharmadown 6.9%ALSO LOWER -PepGendown 44.4% after Phase 2 Freedom trial data